Provided are a traditional Chinese medicine for dispersing lung qi and detoxicating, a preparation method therefor, use thereof, and an analysis method. The traditional Chinese medicine contains a traditional Chinese medicine active extract. The active extract is composed of a first extract and, a second extract, herein the first extract is a water extract or an alcohol-water extract of ephedra, bitter apricot seed, raw gypsum, coix seed, rhizome of swordlike atractylodes, patchouli, Polygonum cuspidatum, verbena, reed rhizome, lepidium seed, pummelo peel, and artemisia annua, the second extract is a water extract or an alcohol-water extract of licorice, and the first extract and the second extract are separately obtained. This traditional Chinese medicine may be used for treating coronavirus diseases, such as novel coronavirus pneumonia.

Disclosed herein are antiviral compositions for treating CoV. In some embodiments, the antiviral compositions include at least 5 components selected from: a therapeutically effect amount of spikenard or an extract thereof; a therapeutically effective amount of at least one mineral; a therapeutically effective amount of at least one vitamin; a therapeutically effective amount of oregano oil or at least one active component included within oregano oil; a therapeutically effective amount of one or more Artemisinins or derivatives or analogs thereof; a therapeutically effective amount of one or more Salvia species or an extract thereof; and a therapeutically effective amount of cardamom oil or an extract thereof.

Disclosed herein are antiviral compositions for treating CoV. In some embodiments, the antiviral compositions include at least 5 components selected from: a therapeutically effect amount of spikenard or an extract thereof; a therapeutically effective amount of at least one mineral; a therapeutically effective amount of at least one vitamin; a therapeutically effective amount of oregano oil or at least one active component included within oregano oil; a therapeutically effective amount of one or more Artemisinins or derivatives or analogs thereof; a therapeutically effective amount of one or more Salvia species or an extract thereof; and a therapeutically effective amount of cardamom oil or an extract thereof.

The food additive includes the following components in weight percent: liquorice—Glycyrrhiza glabra from 1.19% to 47.61%, sweet wormwood—Artemisia annua from 1.19% to 47.61%, quinine bark extract—Cinho from 1.19% to 47.61%, hawthorn extract—Crataegus from 1.19% to 47.61%, dandelion extract—Taraxcum from 1.19% to 47.61%, vitamin C—Ascorbic acid from 1.19% up to 47.61%, DD-Galacturonic acid from 1.19% to 47.61%, apple pectin from 1.19% to 47.61%, bitter orange—Citrus aurantium from 1.19% to 47.61%, ginger—Zingiber officinale from 0.23% to 11.9%, Radix isatidis from 0.23% to 11.9%, Lindera aggregate—0.23% to 11.9%, woad—Isatis indigotica from 0.23% to 9.52%, Torreya nucifera from 0.23% to 9.52%, geranium extract—Pelargonium from 0.23% to 9.52%, Zinc from 0.23% to 2.38% and Sodium Selenite from 0.00119% to 0.04762%.

The food additive includes the following components in weight percent: liquorice—Glycyrrhiza glabra from 1.19% to 47.61%, sweet wormwood—Artemisia annua from 1.19% to 47.61%, quinine bark extract—Cinho from 1.19% to 47.61%, hawthorn extract—Crataegus from 1.19% to 47.61%, dandelion extract—Taraxcum from 1.19% to 47.61%, vitamin C—Ascorbic acid from 1.19% up to 47.61%, DD-Galacturonic acid from 1.19% to 47.61%, apple pectin from 1.19% to 47.61%, bitter orange—Citrus aurantium from 1.19% to 47.61%, ginger—Zingiber officinale from 0.23% to 11.9%, Radix isatidis from 0.23% to 11.9%, Lindera aggregate—0.23% to 11.9%, woad—Isatis indigotica from 0.23% to 9.52%, Torreya nucifera from 0.23% to 9.52%, geranium extract—Pelargonium from 0.23% to 9.52%, Zinc from 0.23% to 2.38% and Sodium Selenite from 0.00119% to 0.04762%.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present disclosure relates to TGF-beta inhibition utilizing certain agents such as Artemisinin and antisense oligonucleotides including OT-101. The present invention also provides the composition comprising the said agents optionally along with one or more additional therapeutic agent, method of treating various viral diseases including COVID-19 and method of use involving said agents. The present invention further provides a substantially pure Artemisinin having a purity of more than 90%. The present invention also provides Artemisinin for use in the treatment of COVID-19. The present invention provides a process of extraction of artemisinin and a composition of matter comprising artemisinin. The present invention also provides a method of treating TGF-beta storm. The present invention also provides a method of use of anti-sense oligonucleotide by suppression of TGF-beta induced proteins including IL-6, TGFBIp.

The present disclosure relates to TGF-beta inhibition utilizing certain agents such as Artemisinin and antisense oligonucleotides including OT-101. The present invention also provides the composition comprising the said agents optionally along with one or more additional therapeutic agent, method of treating various viral diseases including COVID-19 and method of use involving said agents. The present invention further provides a substantially pure Artemisinin having a purity of more than 90%. The present invention also provides Artemisinin for use in the treatment of COVID-19. The present invention provides a process of extraction of artemisinin and a composition of matter comprising artemisinin. The present invention also provides a method of treating TGF-beta storm. The present invention also provides a method of use of anti-sense oligonucleotide by suppression of TGF-beta induced proteins including IL-6, TGFBIp.